Evidence map›Paper›PMID 25288099›Full record

ArticleHealth and quality of life outcomes2014

Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and Neurogenic Module.

Jesús Cuervo, Nacho Castejón, Kristin M Khalaf, Catherine Waweru, Denise Globe, Donald L Patrick

2 registry-linked trialsAbstract readEvaluation StudyValidation Study
In one paragraph

Article in Health and quality of life outcomes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00311376 phase3completednot on this map

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

TypeinterventionalSponsorAllerganRan2006 to 2010Enrolled416ConditionsOveractive BladderArmsbotulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal Saline (Placebo), botulinum toxin Type A (200U), Normal Saline (Placebo)
NCT00461292 phase3completednot on this map

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

TypeinterventionalSponsorAllerganRan2007 to 2010Enrolled275ConditionsOveractive BladderArmsbotulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo), botulinum toxin Type A (200U), Normal saline (Placebo)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Do we agree on health state outcomes? A review of measurement agreement between time-trade off and other utility measures.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  3. Article
  4. Review
  5. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.The European journal of health economics : HEPAC : health economics in prevention and care · 2016
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jesús CuervoLASER Analytica, C/Azcárraga 12 A, Oviedo, 33010, Asturias, Spain. Jesus.Cuervo@la-ser.com.
Nacho Castejón
Kristin M Khalaf
Catherine Waweru
Denise Globe
Donald L Patrick

Funding

Biobehavioral Cancer Prevention and Control Training ProgramR25CA092408 · NCI · UNIVERSITY OF WASHINGTON · PI PATRICK, DONALD LEE · 2001 to 2015
$7.1M
NCI NIH HHS R25 CA092408
6 · The paper itself

Abstract

backgroundGeneric utility instruments may not fully capture the impact and consequences of urinary problems. Condition-specific preference-based measures, developed from previously validated disease-specific patient-reported outcomes instruments, may add relevant information for economic evaluations. The aim of this study was to develop a condition-specific preference-based measure, the Incontinence Utility Index (IUI), for valuing health states associated with urinary problems.

methodsA two-step process was implemented. First, an abbreviated health state classification system was developed from the Incontinence Quality of Life Questionnaire (I-QOL) and Neurogenic Module by applying Rasch modelling, classical psychometrical testing and expert criteria to data from two pivotal trials comprised of neurogenic detrusor overactivity (NDO) patients. Criterion, convergent validity and concordance with the original instrument was assessed in the abbreviated version. Then, a multi-attribute utility function (MAUF) was estimated from a representative sample of the UK non-institutionalized adult general population. Visual analogue and time-trade off (TTO) evaluations were applied in the elicitation process. Predictive validity of the MAUF was tested comparing estimated and direct utility scores.

resultsThe abbreviated health state classification system generated from the NDO sample contained 5 attributes with 3 levels of response and had adequate psychometrical properties: significant differences in scores according to the reduction in the frequency of urinary incontinence episodes [UIE] (p < 0.001); Spearman correlation coefficient with number of daily UIE = -0.43; p < 0.01 and Intraclass Correlation Coefficient (ICC, 95% CI) with the original version = 0.90 (0.89-0.91; p < 0.001). Next, 442 participants were interviewed (398 cases were valid, generating 2,388 TTO evaluations) to estimate the social preferences for derived health states. Mean age was 44.75 years (interquartile range 33.5-55.5) and 60.1% were female. An overall algorithm for the IUI was estimated and transformed onto a dead = 0.00 and full health = 1.00 scale. Model fits were acceptable (R-squared = 0.923 and 0.978). Predictive validity was adequate: ICC (95% CI) = 0.928 (0.648-0.985) and Mean of Absolute Differences = 0.038.

conclusionsThe newly developed IUI is a preference-based measure for urinary problems related to NDO that provides general population-based utility scores with adequate predictive validity.

trial registrationClinicalTrials.gov: NCT00461292, NCT00311376.

Indexed as

Surveys and QuestionnairesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedModels, TheoreticalProgram DevelopmentProgram EvaluationPsychometricsQuality of LifeUnited KingdomUrinary Incontinence

Identifiers

PMID25288099
PMCPMC4196092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.